Upsher-Smith Laboratories, LLC (Upsher-Smith), a United States-based pharmaceutical company, announced on Thursday that it has expanded its fluoxetine product range with the introduction of Fluoxetine Oral Solution, USP, 20mg/5mL.
The product is a generic version of Prozac (fluoxetine) Oral Solution.
Rich Fisher, Upsher-Smith president and COO, said, 'We are very excited to lead this calendar year off with the launch of Fluoxetine Oral Solution. Upsher-Smith has many exciting things in store for 2023 including the opening of our world-class manufacturing facility in Maple Grove, MN, and a rich pipeline of high-quality generic products, positioning the Company for both near-term and future growth.'
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream